Prevalence and Determinants of High-Risk Human Papillomavirus Infection among Women Living in Urban and Rural Communities of Edo State, Nigeria

Authors

  • Okoeguale J. Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua and College of Medicine, Ambrose Alli University, Ekpoma-Nigeria
  • Okome G.B.O. Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua and College of Medicine, Ambrose Alli University, Ekpoma-Nigeria
  • Eifediyi R.A. Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua and College of Medicine, Ambrose Alli University, Ekpoma-Nigeria
  • Eigbefoh J. Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua and College of Medicine, Ambrose Alli University, Ekpoma-Nigeria
  • Olowo S. Department of Medical Microbiology, College of Medicine, Ambrose Alli University, Ekpoma-Nigeria
  • Momoh M. Department of Medical Microbiology, College of Medicine, Ambrose Alli University, Ekpoma-Nigeria

DOI:

https://doi.org/10.20941/2309-4400.2017.05.2

Keywords:

High risk human papillomavirus, cervical cancer, HPV prevalence, Edo State Nigeria.

Abstract

Introduction: Oncogenic human papillomaviruses are predominantly sexually-transmitted pathogens of which several high-risk types are associated with nearly all cases of cervical cancer world especially occurring in women in Sub-Saharan Africa where preventive measures against cervical cancer has been very poor. There are little or very few studies in our setting that have evaluated the various high risk HPV subtypes using polymerase chain reaction, with HPV DNA extraction, amplification and Flow-through hybridization.

This study therefore, aimed to determine the pattern and correlates of high risk human papilloma virus infections in Edo State using pooled data from urban and rural Sub regions of the state as knowledge about the distribution of the HPV types circulating in the communities in different regions of the world would be useful in devising the optimum preventive strategy for high risk HPV infection.

Materials and Methods: This was an analytical cross sectional study of consecutive 290 participants (involving 145 urban and 145 rural participants) in Edo state Nigeria. Enrolled participants who consented to the study were administered structured interviewer questionnaire. Cervical swab sample collection using the female cervical cell collection kit for HPV DNA testing was done to determine the presence of high risk HPV infection. The residual cell suspensions from the female cervical cell collection kit was frozen at -20°C until the desired sample size was achieved. The frozen samples were transported to molecular diagnostics laboratory Nigeria limited, Lagos State Nigeria in iced cold packs for analysis. HPV DNA was detected using the hybribio 21 HPV geno array test kit which uses Polymerase Chain Reaction (PCR), amplification and flow through hybridization.

ResultsA total of 290 participants (n=145 urban women and n=145 rural women) were recruited across both settings. The mean age of the participants was 41.0±11.0 and 37.0± 13.0 for urban and rural participants respectively. The overall prevalence for high risk HPV infection in this study was 23(7.9%) with 11(7.6%) in urban and 12(8.3%) in rural communities (p-value = 0.82). The viral serotypes identified in this study within the urban and rural sub regions of Edo state were types 16,18,31,35,45,51,52 and 58. HPV subtypes 16 and 18 contributed the highest prevalence with 45.5% in the urban setting versus 33.3% in the rural setting, with an overall prevalence of 39.1%. Co-infection of 45 and 58 was highest among urban participants (18.2%) while co-infection of 45 and 52 was highest in rural participants (33.3%). Urban women had variable coinfection (35, 45; 45, 52; 45, 58) whereas in rural women, co-infection occurred with Type 45, 52. Sexual activities irrespective of the number of partners and higher parities were statistically associated with a positive high risk HPV status in both urban and rural participants (p-value 0.041), (p-value 0.001) respectively. There was no statistically significant relationship among circumcision, HIV infection, condom use and HPV positivity in both settings.

Conclusion: The prevalence of high risk HPV infection is comparable among women living in urban and rural communities of Edo state Nigeria, however, variations exist in the pattern of occurrence of high risk human papillomavirus subtypes within these sub regions of the State. Strengthening reproductive and sexual education in both males and females with focus on HPV vaccination, delaying sexual activities and reduction in number of childbirth are strategies which would prevent high risk HPV infection and cervical cancer in these communities.

References

Hussain GA, Saleh H and Ibraheem M. Frequency of Human Papilloma Virus (HPV) subtypes 31,33,35,39 and 45 among Yemeni Women with Cervical Cancer Infectious Agents and Cancer 2015; 10: 29. DOI 10.1186/s13027-015-0026-9

Balogun MR, Odukoya OO, Oyediran MA and Ujomu PI. Cervical Cancer Awareness and Preventive Practices; A challenge for female urban slum dwellers in Lagos, Nigeria. Afr J Reprod Health

[Internet] 2012; 16: 75-82.

Eze J, Umeora O, Obuna J, Egwuatu V and Ejikeme B. Cervical Cancer Awareness and Cervical Screening Uptake at the Mater Misericordiae Hospital, Afikpo, Southeast Nigeria. Annals of African Medicine 2012; 238. https://doi.org/10.4103/1596-3519.102856

World Health Organization. Human Papillomavirus and related cancers, Fact Sheet 2014. WHO/ICO HPV Information Centre. info@hpvcentre.net/www.hpvcentre.net.

Oche MO, Kaoje AU, Gana G and Ango JT. Cancer of the Cervix and Cervical Screening: Current Knowledge, attitude and practices of female health workers in Sokoto, Nigeria in International Journal of Medicine and Medical Sciences 2013; 5(4): 184-190.

Christine HH. Premalignant and Malignant Disorders of the Uterine Cervix, in Current diagnosis and treatment, obstetrics and gynaecology, McGraw-Hill companies Inc, Tenth Edition 2007; 50: 843-848.

Ferlay J, Shin HR, Bray F, Mathers DC and Parkin DM. Cancer Incidence and Mortality Worldwide, IARC Cancer Base 2010; No.10.

Clifford G, Franceschi S, Diaz M, Munoz N and Villa LL. HPV type-distribution in women with and without cervical neoplastic diseases, Vaccine 2006; chap 3(24(3)): S26-S34.

Sowjanya AP, Jain M, Poli UR, Padma S and Das M. Prevalence and Distribution of High-risk Human Papilloma Virus (HPV) types in Invasive Squamous Cell Carcinoma of the Cervix and in normal Women in Andhra Pradesh, India. BMC Infect 2005; 5: 116. https://doi.org/10.1186/1471-2334-5-116

Tristam A and Fiander A. Human Papilloma Virus (including vaccines). Obstet Gynaecol Reprod Med 2007; 17(11): 324. https://doi.org/10.1016/j.ogrm.2007.08.006

Bello FA, Enabor OO and Adewole IF. Human Papilloma Virus Vaccination for Control of Cervical Cancer: A Challenge for Developing Countries in Afr J Reprod Health 2011; 15(1): 25.

Tsuand VD and Levin CE. Making the Case for Cervical Cancer Prevention: what about equity?" In Journals of Reproductive Health Matters 2008; 16(32): 104-112.

Denny L, Quinn M and Sankaranarayanan R. In Screening for Cervical Cancer in Developing Countries. Vaccine 2006; (24)3: 71-77. https://doi.org/10.1016/j.vaccine.2006.05.121

WHO/ICO Information Centre on HPV and Cervical Cancer: HPV and Cervical Cancer in the 2007 Report. Vaccine 2007; 25(3): C1-C230.

Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, et al. Prevalence of Papillomavirus Infection in Women in Ibadan, Nigeria: A Population-Based Study. Br J Cancer 2004; 90: 638-645. https://doi.org/10.1038/sj.bjc.6601515

WHO/ICO. Information Centre on HPV and Cervical Cancer: Human Papillomavirus and Related Cancers in Mali, Summary Report 2010.

[http://www.who.int/hpvcentre/en/]

Kling M and Zeichner JA. The Role of the Human Papillomavirus (HPV) Vaccine in Developing Countries. In International Journal of Dermatology 2010; 4: 377-379. https://doi.org/10.1111/j.1365-4632.2010.04316.x

Executive Summary. Edo State Government Strategic Health Development Plan (2010-2015), Edo State Ministry of Health, March 2010.

Ojeifo O, Magnus M, Joseph O and Eseigbe E. Categorization of Urban Centres in Edo State, Nigeria in IOSR Journal of Business and Management (IOSRJBM); ISSN: 2278-487X 2012; 3(6): PP 19-25. www.iosrjournals.org

Fadahunsi OO, Omoniyi-Esan GO, Banjo AAF, Esimai OA and Osiagwu D, et al. Prevalence of High Risk Oncogenic Human Papillomavirus Types in Cervical Smears of Women Attending Well Woman Clinic in Ile Ife, Nigeria. Gynecol Obstet 2013; 3: 185. https://doi.org/10.4172/2161-0932.1000185

Baseman JG and Koutsky LA. The Epidemiology of Human Papillomavirus Infections. J ClinVirol 2005; 32(Suppl 1): S16-S24. https://doi.org/10.1016/j.jcv.2004.12.008

Arbyn M, Annemie H, Anja D, Freija V, Nancy T, Julie F, et al. Cervical Cancer Screening program and Human Papillomavirus (HPV) Testing part II: update on HPV primary screening-summary. Health technlogy assessment (HTA) Brussels: Belgian Health care Knowledge Center (KCE) 2015; 238Cs. D/2015/10.273/16.

Schnatz PF, Markelova NV, Holmes D, Mandavilli SR and O'Sullivan DM. The prevalence of cervical HPV and cytological abnormalities in association with reproductive factors of rural Nigerian women. J Womens Health 2008; 17: 279-285. https://doi.org/10.1089/jwh.2006.0295

Sally NA, Ayo OF, Eileen OD, Olayinka BO, Richard E, Cosette M, et al. Age-specific Prevalence of Human Papilloma Virus Infection among Nigerian Women in BMC Public Health 2014; 14: 656. http://www.biomedcentral.com/1471-2458/14/656.

Auwal IK, Aminu M, Atanda AT, Tukur J and Sarkinfada F. The Prevalence and Risk Factors of High-risk Human Papillomavirus Infections among women attending gynaecology clinics in Kano, Nothern Nigeria, in Bayero Journal of Pure and Applied Sciences 2013; 6(1): 67-71.

Nicholas HS, Samba OS, Cheick BT, Kamate B and Rokiatou D. Differences in Patterns of High-risk Human Papillomavirus Infection between Urban and Rural Lowresource Settings in BMC Women's Health 2013; 13: 4.

WHO/ICO Information Centre on HPV and Cervical Cancer (2007) HPV and cervical cancer in the 2007. J Vaccine 2007; 25(3): 230.

De Vuyst H, Claeys P, Njiru S, Muchiri L and Steyaert S. Comparison of pap smear, visual inspection with acetic acid, human papillomavirus DNA PCR testing and cervicography Int J Gynaecol Obstet 2005; 89: 120-126. https://doi.org/10.1016/j.ijgo.2005.01.035

Clarke MA, Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Wacholder S, et al. A Population-based, Cross-sectional Study of Age Specific Risk Factors for High-risk Human Papillomavirus Prevalence in Rural Nigeria. Infect Agent Cancer 2011; 6: 12. https://doi.org/10.1186/1750-9378-6-12

Gage JC, Ajenifuja KO, Wentzensen NA, Adepiti AC, Eklund C, et al. The Age-specific Prevalence of Human Papillomavirus and Risk of Cytologic Abnormalities in Rural Nigeria: Implications for Screen-and-treat strategies. Int J Cancer 2012; 130: 2111–2117. https://doi.org/10.1002/ijc.26211

Molano M, Posso H, Weiderpass E, van den Brule AJ, Ronderos M, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002; 87: 324-333. https://doi.org/10.1038/sj.bjc.6600442

Didelot-Rousseau M, Nagot N, Costes-Martineau V, Vallès X and Ouedraogo A. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006; 95: 355-362. https://doi.org/10.1038/sj.bjc.6603252

Chan PK, Chang AR, Cheung JL, Chan DP, Xu LY, et al. Determinants of cervical human papillomavirus infection: differences between high- and lowoncogenic risk types. J Infect Dis 2002; 185: 28-35. https://doi.org/10.1086/338010

Xi LF, Toure P, Critchlow CW, Hawes SE and Dembele B. Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35years of age. Int J Cancer 2003; 103: 803-809. https://doi.org/10.1002/ijc.10876

Stanley M, Pinto LA and Trimble C. Human Papillomavirus Vaccines— Immune Responses. Vaccine 2012; 30(Suppl 5): F83-7. https://doi.org/10.1016/j.vaccine.2012.04.106

Moodley JR, Constant D, Hoffman M, Salimo A, Allan B, Rybicki E, et al. Human papilloma virus prevalence, viral load and precancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: a crosssectional study. BMC Cancer 2009; 9: 275-282. https://doi.org/10.1186/1471-2407-9-275

Oliveira LH, Rosa ML and Cavalcanti SM. Patterns of genotype distribution in multiple human papillomavirus infections. Clin Microbiol Infect 2008; 14: 60-65. https://doi.org/10.1111/j.1469-0691.2007.01887.x

Soto SC, Camargo M, Sanchez R and Leon S. prevalence of infection with high risk HPV in women in Colombia. Journal Compilation European Society of Clinical Microbiology and Infectious Diseases, CMI 2009; 15: 93-102.

Downloads

Published

2017-12-30

Issue

Section

Articles